Life does not get any easier for Pfizer (PFE). Forget generics. Now other drug firms are ganging up on them. Merck (MRK) and Schering-Plough are going to offer drug that combines their cholestoral drug with Pfizer blockbuster Lipitor. Its patent expires in three years.
Pfizer has defied gravity this year. Its stock trades at $25.66. In July, it was down to $22.28. The company has cut considerable staff. But, unless it has some rabbits in the pipeline hat, life is about to get very rough.
Douglas A. McIntyre
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.